CEL-SCI Corporation
New York Stock Exchange AmericanRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- CEL-SCI Corporation (NYSE American: CVM), a biotechnology company founded in 1983 and headquartered in Vienna, Virginia, engages in the research, development and manufacturing of immunotherapy products for cancer, autoimmune and infectious diseases; its lead investigational product is Multikine (Leukocyte Interleukin, Injection), a defined mixture of natural cytokines administered locally as a first-line neoadjuvant therapy before surgery to stimulate the immune response in newly diagnosed, resectable locally advanced primary squamous cell carcinoma of the head and neck (SCCHN) patients with no lymph node involvement and low PD-L1 tumor expression; Multikine has demonstrated significant 5-year overall survival benefits of 73% versus 45% in controls (hazard ratio 0.35) in the target population from the completed 928-patient Phase 3 trial, with high rates of pre-surgical tumor reductions (PSR) and downstaging (PSD), no added toxicity and no safety signals across approximately 740 patients tested; the company also advances LEAPS (Ligand Epitope Antigen Presentation System) technology, a peptide vaccine platform for rheumatoid arthritis (CEL-2000, CEL-4000), pandemic influenza (LEAPS-H1N1-DC) and other autoimmune/infectious indications. CEL-SCI operates primarily in North America with manufacturing near Baltimore, Maryland, and holds licensing agreements including exclusive rights granted to Teva Pharmaceutical for Israel, Turkey, Serbia and Croatia; Orient Europharma for Taiwan, Singapore, Malaysia, Hong Kong, the Philippines, South Korea, Australia and New Zealand; and Byron Biopharma for South Africa. Recent developments include FDA clearance in May 2024 for a 212-patient confirmatory registration study of Multikine in the target population, with enrollment planned to begin in Q1 2025 and full enrollment by Q2 2026; a July 2025 agreement to partner with a leading Saudi Arabian pharmaceutical company for regulatory filing and commercialization of Multikine in head and neck cancer via Saudi Food and Drug Authority Breakthrough Medicine Designation, supported by interest from Saudi investment funds; selection of Ergomed as clinical research organization; executive changes such as Patricia B. Prichep assuming Chief Financial and Operations Officer duties in November 2024 and Giovanni Selvaggi, MD, as Acting Chief Medical Officer since May 2024; and multiple recent public offerings totaling approximately $8.2 million to fund operations.
CEL-SCI Reports Fiscal Second Quarter 2026 Results
CEL-SCI Announces Closing of Public Offering
CEL-SCI Corporation Announces Pricing of Public Offering
CEL-SCI Enters Strategic Agreement with Amarox for the Registration, Commercialization, and Distribution of Multikine in Saudi Arabia
Itaú Unibanco Holding files 2025 Form 20-F with the SEC and the CVM
Cel-Sci (NYSEAMERICAN:CVM) Shares Down 0.9% – What’s Next?
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Up 6.9% – Time to Buy?
CEL-SCI Reports Fiscal First Quarter 2026 Results
Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 6.5% – What’s Next?
CEL-SCI Reports Fiscal 2025 Results
CEL-SCI Presentation at LD Micro "Main Event" Available on Tuesday, October 21, 2025
CEL-SCI Corporation to Present at LD Micro "Main Event" Investor Conference
Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension
CEL-SCI Announces Closing of $10 Million Public Offering
CEL-SCI Announces Pricing of $10 Million Public Offering
CEL-SCI Announces Proposed Public Offering
CEL-SCI Reports Fiscal Third Quarter 2025 Financial Results
CEL-SCI's Multikine Head and Neck Cancer Immunotherapy Breakthrough Medicine Designation Filed in Saudi Arabia: Allows for Patient Access and Reimbursement/Sale Upon Granting of the Designation Which Takes Approximately 60 Days Based on SFDA Timeline
CEL-SCI Announces Closing of $5.7 Million Offering Priced At-The-Market Under NYSE American Rules
CEL-SCI to Sign Partnership Agreement With Leading Saudi Arabian Pharma Company for Multikine in the Treatment of Head & Neck Cancer